CD4 and cancer: Further, the effect of MEK inhibitors on CD4+ T cells raises questions about the immunosuppressive effects of using MEK inhibitors in cancer treatment, especially as current clinical trials combine MEK inhibitors with checkpoint-blockade inhibitors (Zhao and Adjei, 2014; Vella et al., 2014).